查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1627724

全球處方藥市場：預測（2025-2030）

Global Prescription Drugs Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 155 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球處方藥市場規模預計將以 4.67% 的複合年成長率成長，從 2025 年的 12,680.08 億美元成長到 2030年終的15,930.19 億美元。

處方藥比非處方藥 (OTC) 更有效。因此，使用不當會導致嚴重的副作用。這些藥物是根據醫生的處方箋提供給顧客的。您可能已經注意到，醫生處方箋記事本或大多數藥房標誌上的 Rx 符號是醫療處方符號。全球藥品支出的成長可能會對預測期內的市場成長產生重大影響。

關鍵促進因素之一是特種藥物的高成本和治療可用性的擴大。罕見疾病的流行將在預測期內進一步提振市場。全球慢性病的增加將在預測期內進一步推動處方藥銷售。此外，全球癌症病例數的增加也推動了預測期內的市場擴張。

此外，世界老年人數量的增加大大提高了預測期內的市場成長前景。世界已開發地區，尤其是北美，預計將在處方藥市場中佔據主要佔有率。同時，由於需要治療的人數眾多，亞太地區被認為是成長最快的地區之一。此外，透過更好的醫療設施改善醫療基礎設施的大量投資進一步為預測期內的市場成長提供了機會。

按類型分類，市場分為學名藥、孤兒藥和其他處方藥。依應用分類，全球處方藥市場分為糖尿病、腫瘤、心血管疾病、自體免疫疾病等。市場依分銷管道分為院內藥局、藥局及零售藥局及網路藥局。

處方藥市場促進因素

  • 世界各地慢性病的增加

人們廣泛觀察到全世界慢性病盛行率顯著增加。其主要原因是都市化的進步和不健康的居住環境的建立。此外，全球老年人口的增加導致與老齡化相關的疾病增加，進一步增加了慢性病的增加，並推動了預測期內的市場成長。阿茲海默症、心血管疾病、肥胖和糖尿病等疾病屬於慢性病。例如，根據阿茲海默症國際組織 (ADI) 的數據，截至 2020 年，全球有超過 5,500 萬人患有失智症。這一數字預計在 20 年內將增加近一倍，到 2030 年達到 7,800 萬，到 2050 年將達到 1.39 億。其中大部分在開發中國家有所增加。

此外，癌症發生率上升進一步推動了預測期內的市場成長。例如，根據國家醫學圖書館的數據，2022 年印度的癌症發生率估計為 1,461,427 人。粗率是每百萬人口 100.4 人。在印度，九分之一的人一生中會罹患癌症。肺癌和乳癌是男性和女性最常見的癌症。淋巴球白血病（男孩：29.2%，女孩：24.2%）是印度兒童（0-14 歲）最常見的癌症。與 2020 年相比，2025 年癌症發生率預計將增加 12.8%。

心血管疾病盛行率的增加進一步促進了處方藥銷售，推動了預測期內的市場成長。根據疾病預防控制中心的數據，由心臟和血管疾病組成的心血管疾病是全球死亡和殘疾的第一大原因。這種疾病的主要危險因子包括高血壓或高血壓，預計全球整體每年將導致 1,000 萬人死亡。

為什麼要購買這份報告？

  • 富有洞察力的分析：獲得涵蓋關鍵和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、行業和其他子區隔。
  • 競爭格局：了解世界主要企業採取的策略策略，並了解透過正確的策略滲透市場的潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中發現新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業有用且具有成本效益。

它有什麼用？

產業/市場考量、商機評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、監管影響、新產品開發、競爭訊息

調查範圍

  • 2022年至2030年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 區域收益成長和預測分析，包括細分市場和國家
  • 公司簡介（主要是策略、產品、財務資訊、主要動態等）

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析

第5章全球處方藥市場分析：按類型

  • 介紹
  • 非專利的
  • 孤兒藥
  • 其他

第6章全球處方藥市場分析：依應用分類

  • 介紹
  • 糖尿病
  • 瘤
  • 心血管疾病
  • 自體免疫疾病
  • 其他

第7章全球處方藥市場分析：按分銷管道

  • 介紹
  • 醫院藥房
  • 藥局和零售藥局
  • 網路藥房

第8章全球處方藥市場分析：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 其他
  • 中東/非洲
    • 阿拉伯聯合大公國
    • 以色列
    • 沙烏地阿拉伯
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 其他

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 併購/協議/合作
  • 競爭對手儀表板

第10章 公司簡介

  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novo Nordisk A/S
  • Bayer AG
  • Gilead Sciences, Inc
  • Eli Lilly and Company
  • Allergan
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
簡介目錄
Product Code: KSI061613887

The global prescription drug market is estimated to augment at a CAGR of 4.67%, increasing from US$1,268.008 billion in 2025 to US$1,593.019 billion by the end of 2030.

Prescription drugs are more potent in comparison to over-the-counter (OTC) drugs. Hence, their inappropriate use may lead to serious side effects. These medicines are handed over to customers based on doctors' prescriptions. One might have noticed on the doctor's prescription notepads and signs in most pharmacies that the symbol Rx is the symbol for medical prescription. Growing global pharmaceutical spending will have a significant impact on fueling the market growth during the forecast period.

One of the main drivers is the high cost of specialty medicines and the growing use of medical treatments. The prevalence of rare disorders further propels the market during the forecast period. The increasing number of chronic diseases worldwide is further raising the sales of prescription drugs in the forecast period. The growing number of cancer incidences worldwide is also driving the market expansion during the forecast period.

Furthermore, the growing number of elderly individuals worldwide has significantly raised market growth prospects in the forecast period. The developed regions of the world, particularly North America, is projected to hold a significant share in the prescription drug market. On the other hand, the Asia-Pacific region is regarded as one of the fastest-growing, owing to the prevalence of a large population requiring treatment. In addition, significant investments in improving healthcare infrastructure with better health facilities are further providing an opportunity for the market to grow during the forecast period.

Based on type, the market is categorized as generics, orphan drugs, and other prescription drugs. By application, the global prescription drug market is segregated into diabetes, oncology, cardiovascular diseases, autoimmune diseases, and others. The market is segmented by distribution channel into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies.

Global Prescription Drugs Market Drivers

  • Rising incidences of chronic diseases worldwide

It has been observed on a wide scale that there is a significant rise in the global chronic disease burden. One of the major reasons includes growing urbanization and the adoption of unhealthy living conditions. Additionally, the growing geriatric population worldwide is contributing to the rise of age-associated diseases, further augmenting chronic disease growth and fueling the market growth in the forecast period. Diseases such as Alzheimer's disease, cardiovascular disease, obesity, and diabetes are some chronic diseases. For instance, according to Alzheimer's Disease International (ADI), there were over 55 million people worldwide who are living with dementia as of 2020. The number will almost double in 20 years, reaching 78 million in 2030 and 139 million in 2050. Much of the increase will be in developing countries.

The rising incidences of cancer are further providing an impetus, fueling the market growth in the forecast period. For instance, according to the National Library of Medicine, the estimated incidence of cancer cases in 2022 was 14,61,427 in India. With the crude rate, it was 100.4 cases per 1,00,000 population. In India, one in nine people develops cancer in their lifetime. In males and females, lung and breast cancers are most often found. Lymphoid leukemia (among boys: 29.2% and girls: 24.2%) was the most prevalent childhood (0-14 years) cancer site in India. The incidence of cancer cases is estimated to increase by 12.8 percent in 2025 compared to 2020.

The growing prevalence of cardiovascular diseases is further contributing to the sales of prescription drugs, fueling the market growth in the forecast period. As per the CDC, cardiovascular diseases, comprising disorders of the heart and blood vessels, are ranked as the number one cause of death and disability globally. The major risk factors for this disease include high blood pressure or hypertension, which are attributed to causing a predicted 10 million deaths globally every year.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Global Prescription Drugs market is segmented and analyzed as follows:

By Type

  • Generics
  • Orphan Drugs
  • Others

By Application

  • Diabetics
  • Oncology
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Drug Stores & Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Israel
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY TYPE

  • 5.1. Introduction
  • 5.2. Generics
  • 5.3. Orphan Drugs
  • 5.4. Others

6. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY APPLICATION

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Oncology
  • 6.4. Cardiovascular Diseases
  • 6.5. Autoimmune Diseases
  • 6.6. Others

7. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Drug Stores & Retail Pharmacy
  • 7.4. Online Pharmacy

8. GLOBAL PRESCRIPTION DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Others
  • 8.5. Middle East and Africa
    • 8.5.1. United Arab Emirates
    • 8.5.2. Israel
    • 8.5.3. Saudi Arabia
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Novartis AG
  • 10.2. Pfizer Inc.
  • 10.3. Sanofi
  • 10.4. Johnson & Johnson Services, Inc.
  • 10.5. Merck & Co., Inc.
  • 10.6. AbbVie Inc.
  • 10.7. GlaxoSmithKline plc.
  • 10.8. AstraZeneca
  • 10.9. Bristol-Myers Squibb Company
  • 10.10. Amgen Inc.
  • 10.11. Teva Pharmaceutical Industries Ltd.
  • 10.12. Novo Nordisk A/S
  • 10.13. Bayer AG
  • 10.14. Gilead Sciences, Inc
  • 10.15. Eli Lilly and Company
  • 10.16. Allergan
  • 10.17. Takeda Pharmaceutical Company Limited
  • 10.18. Boehringer Ingelheim International GmbH